Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study.

Autor: Persano M; Medical Oncology, University Hospital of Cagliari, Cagliari, Italy., Rimini M; Department of Medical Oncology, IRCCS San Raffaele Hospital, Via Olgettina n. 60, Milan, Italy. margherita.rimini@gmail.com., Tada T; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan., Suda G; Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan., Shimose S; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, 830-0011, Japan., Kudo M; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Higashi-Osaka, Japan., Cheon J; Department of Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea., Finkelmeier F; Department of Internal Medicine 1, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany., Lim HY; Department of Medicine, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, South Korea., Rimassa L; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.; Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy., Presa J; Liver Unit-CHTMAD, Vila Real, Portugal., Masi G; Unit of Medical Oncology 2, University Hospital of Pisa, Pisa, Italy.; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Yoo C; Department of Oncology, ASAN Medical Center, University of Ulsan College of Medicine, 88, Olympic-Ro 43-gil, Songpa-gu, Seoul, 05505, Korea., Lonardi S; Oncology Unit 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy., Tovoli F; Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni 15, Bologna, Italy., Kumada T; Department of Nursing, Gifu Kyoritsu University, Ogaki, Japan., Sakamoto N; Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan., Iwamoto H; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, 830-0011, Japan., Aoki T; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Higashi-Osaka, Japan., Chon HJ; Department of Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea., Himmelsbach V; Department of Internal Medicine 1, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany., Pressiani T; Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy., Kawaguchi T; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, 830-0011, Japan., Montes M; Liver Unit-CHTMAD, Vila Real, Portugal., Vivaldi C; Unit of Medical Oncology 2, University Hospital of Pisa, Pisa, Italy.; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Soldà C; Oncology Unit 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy., Piscaglia F; Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni 15, Bologna, Italy., Hiraoka A; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan., Sho T; Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan., Niizeki T; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, 830-0011, Japan., Nishida N; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Higashi-Osaka, Japan., Steup C; Department of Internal Medicine 1, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany., Iavarone M; Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy., Di Costanzo G; Department of Hepatology, 80131, Naples, Italy., Marra F; Dipartimento di Medicina Sperimentale e Clinica, Università di Firenze, Firenze, Italy., Scartozzi M; Medical Oncology, University Hospital of Cagliari, Cagliari, Italy., Tamburini E; Department of Oncology and Palliative Care, Cardinale G Panico, Tricase City Hospital, Tricase, Italy., Cabibbo G; Section of Gastroenterology and Hepatology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, 90127, Palermo, Italy., Foschi FG; Department of Internal Medicine, Ospedale per gli Infermi di Faenza, Faenza, Italy., Silletta M; Division of Medical Oncology, Policlinico Universitario Campus Bio-Medico, Rome, Italy., Hirooka M; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan., Kariyama K; Department of Gastroenterology, Okayama City Hospital, Okayama, Japan., Tani J; Department of Gastroenterology and Hepatology, Kagawa University, Kagawa, Japan., Atsukawa M; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan., Takaguchi K; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan., Itobayashi E; Department of Gastroenterology, Asahi General Hospital, Asahi, Japan., Fukunishi S; Department of Gastroenterology, Osaka Medical and Pharmaceutical University, Osaka, Japan., Tsuji K; Center of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan., Ishikawa T; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan., Tajiri K; Department of Gastroenterology, Toyama University Hospital, Toyama, Japan., Ochi H; Hepato-biliary Center, Japanese Red Cross Matsuyama Hospital, Matsuyama, Japan., Yasuda S; Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan., Toyoda H; Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan., Ogawa C; Department of Gastroenterology, Japanese Red Cross Takamatsu Hospital, Takamatsu, Japan., Nishimura T; Division of Gastroenterology and Hepatology, Department of Internal medicine, Hyogo Medical University, Nishinomiya, Japan., Hatanaka T; Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan., Kakizaki S; Department of Clinical Research, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan., Shimada N; Division of Gastroenterology and Hepatology, Otakanomori Hospital, Kashiwa, Japan., Kawata K; Department of Hepatology, Hamamatsu University School of Medicine, Hamamatsu, Japan., Tada F; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan., Ohama H; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan., Nouso K; Department of Gastroenterology, Okayama City Hospital, Okayama, Japan., Morishita A; Department of Gastroenterology and Hepatology, Kagawa University, Kagawa, Japan., Tsutsui A; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan., Nagano T; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan., Itokawa N; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan., Okubo T; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan., Arai T; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan., Imai M; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan., Kosaka H; Department of Surgery, Kansai Medical University, Osaka, Japan., Naganuma A; Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan., Koizumi Y; Department of Gastroenterology, Okayama City Hospital, Okayama, Japan., Nakamura S; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan., Kaibori M; Department of Surgery, Kansai Medical University, Osaka, Japan., Iijima H; Division of Gastroenterology and Hepatology, Department of Internal medicine, Hyogo Medical University, Nishinomiya, Japan., Hiasa Y; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan., Cammarota A; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.; Drug Development Unit, Sarah Cannon Research Institute UK, London, UK., Burgio V; Department of Medical Oncology, IRCCS San Raffaele Hospital, Via Olgettina n. 60, Milan, Italy., Cascinu S; Department of Oncology, IRCCS San Raffaele Scientific Institute Hospital, Vita-Salute San Raffaele University, Milan, Italy., Casadei-Gardini A; Department of Oncology, IRCCS San Raffaele Scientific Institute Hospital, Vita-Salute San Raffaele University, Milan, Italy.
Jazyk: angličtina
Zdroj: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2023 Aug; Vol. 149 (9), pp. 5591-5602. Date of Electronic Publication: 2022 Dec 13.
DOI: 10.1007/s00432-022-04512-1
Abstrakt: Purpose: The purpose of this study is to compare response rates of lenvatinib and atezolizumab plus bevacizumab, in first-line real-world setting.
Methods: Overall cohort included Western and Eastern hepatocellular carcinoma (HCC) patient populations from 46 centres in 4 countries (Italy, Germany, Japan, and Republic of Korea).
Results: 1312 patients were treated with lenvatinib, and 823 patients were treated with atezolizumab plus bevacizumab. Objective response rate (ORR) was 38.6% for patients receiving lenvatinib, and 27.3% for patients receiving atezolizumab plus bevacizumab (p < 0.01; odds ratio 0.60). For patients who achieved complete response (CR), overall survival (OS) was not reached in both arms, but the result from univariate Cox regression model showed 62% reduction of death risk for patients treated with atezolizumab plus bevacizumab (p = 0.05). In all multivariate analyses, treatment arm was not found to be an independent factor conditioning OS. Comparing ORR achieved in the two arms, there was a statistically significant difference in favor of lenvatinib compared to atezolizumab plus bevacizumab in all subgroups except for Eastern patients, Child-Pugh B patients, presence of portal vein thrombosis, α-feto-protein ≥ 400 ng/mL, presence of extrahepatic disease, albumin-bilirubin (ALBI) grade 2, and no previous locoregional procedures.
Conclusion: Lenvatinib achieves higher ORR in all patient subgroups. Patients who achieve CR with atezolizumab plus bevacizumab can achieve OS so far never recorded in HCC patients. This study did not highlight any factors that could identify patient subgroups capable of obtaining CR.
(© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: